CGON vs CTKB: fair value comparison
CG Oncology, Inc. and Cytek Biosciences, Inc. · Updated 2026-10-19
CGON has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CTKB is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, CGON currently ranks higher by quality score.
| CGON | CTKB | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $59.85 | $5.25 |
| 12-month range | $37.37–$80.68 | $3.35–$6.09 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #154 of 301 Healthcare | #155 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: CGON fair value analysis · CTKB fair value analysis